SCHOTT Pharma invests in sterile cartridge production in Hungary

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Expansion/Expansion SCHOTT Pharma invests in sterile cartridge production in Hungary 04.06.2025 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. SCHOTT Pharma invests in sterile cartridge production in Hungary

June 4, 2025, Hungary, Lukácsháza

• SCHOTT Pharma breaks ground for a new production facility for ready-to-use cartridges in Hungary
• Its investment of over EUR 100 million is part of the company’s expansion strategy to meet the growing market demand for high-value solutions
• The new production facility will be built at SCHOTT Pharma's existing site in Lukácsháza and will create over 100 new jobs

SCHOTT Pharma, a pioneer in drug containment and delivery solutions, is investing more than 100 million euros in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges. Following the opening of a new facility for prefillable glass syringes at the site in 2024, the company has now broken ground for another facility that will add further manufacturing capacity for high-value solutions (HVS). The move aligns with the company’s expansion strategy to increase its share of these high-margin products. “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields. That is why we are investing more than 100 million euros in our plant in Hungary,” said Andreas Reisse, CEO of SCHOTT Pharma. RTU cartridges are used to store biologics, GLP-1 drugs, insulin, or hormone therapies to treat diabetes, obesity, or other immunological diseases. The new facility will bring over 100 additional jobs to the region.

Today, SCHOTT Pharma's Lukácsháza site already plays an important role in supplying the global industry with drug containment solutions and delivery systems. In June 2024, the company opened a new state-of-the-art facility at the site for high-quality prefillable glass syringes, which are widely used to store GLP-1 therapies, critical vaccines, and biologics. Since then, with 120 new employees on board, production has started, and further production capacity has been added.